EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study

Angelo Armandi iD, Helena Bespaljko, Alexander Mang, Yvonne Huber, Maurice Michel, Christian Labenz iD, Peter R Galle, Manjusha Neerukonda, Elisabetta Bugianesi, Detlef Schuppan iD, Jörn M Schattenberg iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17941 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Angelo Armandi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Division of Gastroenterology and Hepatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Insulin Resistance, Proof of Concept Study, Diet, Gluten-Free. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Leibniz-Gemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current management of metabolic dysfunction‐associated steatotic liver disease (MASLD) relies on lifestyle intervention. Prior studies have shown that nutritional wheat amylase trypsin inhibitors (ATI) activate toll‐like receptor 4 on intestinal myeloid cells to enhance intestinal and extra‐intestinal inflammation, including the promotion of murine MASLD, insulin resistance and liver fibrosis.

Aims

We aimed to assess the impact of ATI (gluten)‐free diet in liver as well as metabolic parameters of biopsy‐proven MASLD patients.

Methods

We performed a 6‐week, proof‐of‐concept 1:1 randomised controlled trial of an ATI‐free diet. The controls followed a balanced diet recommended by the German Nutrition Society. We assessed changes in controlled attenuation parameter (CAP), body mass index (BMI) and homeostatic model assessment of insulin resistance (HOMA‐IR). Patient‐reported outcomes were assessed by the CLDQ‐NASH questionnaire. Forty‐five patients were consecutively enrolled (21 in the intervention arm and 24 in the control arm).

Results

Three patients from each arm discontinued the study. In the ATI‐free diet group, a significant decrease in BMI ( p = 0.018), CAP ( p = 0.018) and HOMA‐IR ( p = 0.042) was observed at 6 weeks. The mean difference in CAP between the two arms at week 6 was 30.5 dB/m ( p = 0.039), with a delta significantly higher in the ATI‐free diet group ( p = 0.043). Only an ATI‐free diet could achieve a significant improvement in CLDQ‐NASH domains ( p value for total scoring: 0.013).

Conclusions

A short‐term ATI‐free diet leads to significant improvements in liver and metabolic parameters, as well as patient‐reported outcomes with good tolerability. A larger follow‐up study is justified to corroborate these findings. Clinical trial number: NCT04066400.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceProof of Concept StudyDiet, Gluten-FreeHumansFemaleMaleMiddle AgedAdultBody Mass IndexFatty LiverAgedGlutensNon-alcoholic Fatty Liver Disease

Substanzen

Glutens

Autor:innen und Institutionen

  • Department of Medical Sciences, Division of Gastroenterology and Hepatology, University of Turin, Turin, Italy.
  • Metabolic Liver Disease Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
  • University Medical Center, Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg-University, Mainz, Germany.
  • Beth Israel Deaconess Medical Center, Division of Gastroenterology, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.

ORCID-Profile: Angelo Armandi, Christian Labenz, Detlef Schuppan, Jörn M Schattenberg

Förderung

  • Deutsche Forschungsgemeinschaft
  • Leibniz-Gemeinschaft

Zitieren

APA

Armandi, A., Bespaljko, H., Mang, A., Huber, Y., Michel, M., Labenz, C., Galle, P. R., Neerukonda, M., Bugianesi, E., Schuppan, D., & Schattenberg, J. M. (2024). Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17941

Vancouver

Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, et al. Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17941

BibTeX
@article{Armandi2024,
  author = {Armandi, Angelo and Bespaljko, Helena and Mang, Alexander and Huber, Yvonne and Michel, Maurice and Labenz, Christian and Galle, Peter R and Neerukonda, Manjusha and Bugianesi, Elisabetta and Schuppan, Detlef and Schattenberg, Jörn M},
  title = {Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17941}
}
Kostenlos starten →